SUMMARY Electrophysiological studies were conducted in 13 patients with normal sinus node function and 14 with sinus node dysfunction before and after intravenous lidocaine. Mean ± SEM sinus cycle length significantly shortened from 810 ± 34.3 to 774 ± 34.3 msec in patients with normal sinus node (P < 0.001) and from 1061 ± 67.6 to 1016 ± 64.5 msec in patients with sinus node dysfunction (P < 0.025) after lidocaine. Mean sinus recovery time was 1027 ± 49.4 before and 1026 ± 52.5 msec after lidocaine in patients with normal sinus node (NS) and 1269 ± 97.7 before and 1170 ± 73.8 msec after lidocaine in patients with sinus node dysfunction (P < 0.05). Mean calculated sinoatrial conduction time was 87 + 9.5 before and 90 ± 9.2 msec after lidocaine in patients with LIDOCAINE has been associated with the development of sinus arrest in some patients during or following intravenous administration.'`8 Despite this, only one systematic evaluation of lidocaine effects on human sinus node and atrium has been done.9
LIDOCAINE has been associated with the development of sinus arrest in some patients during or following intravenous administration.'`8 Despite this, only one systematic evaluation of lidocaine effects on human sinus node and atrium has been done.9
In the present study, we have used atrial stimulation techniques to evaluate the electrophysiological effects of lidocaine on sinus node and atrium in patients with and without sinus node dysfunction. Methods 
Patient Selection
The study group was composed of 27 patients undergoing electrophysiological studies because of suspected tachyarrythmias (6), conduction defects (11) , and sinoatrial dysfunction (10) . Thirteen patients (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) were classified as having normal sinoatrial function. Criteria for inclusion in this group were as follows: 1) no history of documented atrial flutter or fibrillation; 2) absence of persistent sinus bradycardia, sinoatrial block, or sinus arrest; 3) normal sinus recovery times (less than 1680 msec) and calculated sinoatrial conduction times (less than 152 msec);'0' II 4) normal atrial effective and functional refractory periods (less than 350 and 400 msec) during sinus rhythm. '2 Fourteen of the patients had sinoatrial dysfunction as defined by the presence of one or more of the following abnormalities: 1) persistent resting sinus bradycardia (sinus rates less than 60/min) (14 to 23); 2) documented recurrent episodes of sinoatrial block (24); 3) abnormal sinus nodal response to atrial extrastimulus testing, e.g., presence of normal sinus node (NS) and 80 i 10.3 before and 96 ± 10.2 msec after lidocaine in patients with sinus node dysfunction (P < 0.001). Mean atrial effective and functional refractory periods were not significantly changed with lidocaine.
Thus lidocaine shortened sinus cycle length in both groups, without affecting atrial refractoriness. Lidocaine appeared to depress perinodal tissue only in patients with sinus node dysfunction. The abbreviation of sinus recovery time in patients with sinus node dysfunction could reflect increased sinus automaticity and/or increased perinodal refractoriness, allowing entrance block to occur. This mechanism may explain why sinus arrest has been noted in some patients during lidocaine administration.
only Zone I (nonreset due to interference) response with absence of sinus reset (25);1' 4) prolonged atrial effective and functional refractory periods (26 and 27).
Electrophysiological Studies
All patients were in sinus rhythm and none had had cardiac medications for at least 72 hours before electrophysiological study. Five of the patients (6, 7, 9, 17 and 27) were on a maintenance dose (0.25 mg) of digoxin, which was withheld three days before the study. Informed written consent was obtained from all patients. His bundle electrograms were recorded using a tripolar catheter passed through a femoral vein.10 A quadripolar catheter was positioned at the high right atrium near the vicinity of sinus node for atrial pacing (distal 2 poles) and for recording high right atrial electrograms (proximal 2 poles). Recordings were obtained on a multichannel oscilloscopic photographic recorder (DR-20 Electronics for Medicine) at paper speeds of 100 and 200 mm/sec. Simultaneous electrocardiographic leads I, II, III, and V, were also recorded.
Atrial pacing was performed at increasing rates in 10 beats/min increments. Sinus node recovery time was defined as the interval between the last paced P wave to the first spontaneous P wave after sudden cessation of pacing at rates ranging from 60 to 150 beats/min. For purposes of comparison before and after lidocaine, three sinus recovery times were measured and averaged at a paced rate of 130/min.1' Maximum sinus node recovery time was defined as the longest atrial asystolic period after sudden cessation of pacing at any of the tested heart rates.
Atrial effective and functional refractory periods were measured with atrial extrastimulus technique at an equivalent driven atrial cycle length before and after lidocaine in 24 patients, 11 with normal, and 13 with abnormal sinoatrial function. In the remaining three patients, these were measured during sinus rhythm (not at equivalent sinus length) and thus were not utilized for comparison pur-LIDOCAINE EFFECTS ON SINUS NODE/Dhingra et al. 880 870  997 1103  1130 1120  51  48  220 210 280 270   2/62/M   850 800  1070 1010  1070 1010  88  90   ----3/37/M   720 680  950 940  1060 960  73  77  270 260 290 During atrial extrastimulus testing, a zone of sinus nonreset due to interference was defined in all patients both before and during lidocaine administration. This zone (mean ± SEM) accounted for the last 25 ± 1.9% of the sinus cycle length before and 24 1.8% during lidocaine infusion (NS) . Similarly, the zone of sinus reset was unchanged with lidocaine, accounting for 27 ± 2.9% of sinus cycle prior to and 29 ± 2.9% following lidocaine (NS). Zones of sinus interpolation were defined in two patients before lidocaine administration. In one of these, interpolated responses were abolished by lidocaine. In the remaining patient, there was no change in the zone of interpolation with lidocaine. One 20 Ryden and co-workers2' reported the effects of intravenous lidocaine bolus (1 mg/kg) on heart rate in 21 patients with sinus bradycardia and acute myocardial infarction. They demonstrated a significant increase in sinus rate ranging from 3.7 to 6.7 beats/min in 19 of 21 patients between 2 to 4 min after lidocaine administration. However, in two patients, transient junctional and idioventricular rhythm developed with disappearance of sinus rhythm following lidocaine.
The electrophysiological basis for the above cases is unknown.'-8, 21 Depressed sinus automaticity and/or depressed sinoatrial conduction through perinodal tissue (S-A block) are possible explanations for the sinus bradycardia or arrest in these patients receiving lidocaine. Recent intracardiac catheter techniques allow more direct evaluation of sinoatrial function' 1-2 but have not been used extensively to evaluate the effects of lidocaine. Roos and Dunning9 demonstrated unchanged sinus node recovery times in 12 patients with normal sinus node function and seven with sinus node dysfunction after lidocaine (100 mg bolus).
The present study suggests that lidocaine in therapeutic doses (1 mg/kg bolus followed by 2-4 mg/minute drip) enhances sinus nodal automaticity in patients both with and without sinus node dysfunction, as manifested by small but significant decreases in sinus cycle length. This finding is in agreement with Ryden's studies in patients,21 but is in contrast with animal experimental studies. Lieberman et al. 22 and Mandel et al.23 reported negative chronotropic effects with large doses (5 to 10 mg/kg) of lidocaine in canines and rabbits. The effect of lidocaine may be vagally-mediated. Lieberman and co-workers22 demonstrated that under conditions of increased vagal activity (vagal stimulation) lidocaine maintained its effect of increasing the rate of sinus node, suggesting that lidocaine could be vagolytic.
Thus augmentation of heart rate produced by lidocaine observed in our study may reflect vagolysis and/or betasympathetic stimulation (central). Experimental studies by Kao and Jalar24 demonstrated that increases in cardiac output and arterial blood pressure resulting from lidocaine were abolished in decerebrate and vagotomized dogs. In the same experiments, through cross-circulation techniques, they showed that the cardiovascular effects of lidocaine were central (on autonomic nerve centers) rather than peripheral. Lidocaine has also been shown to cause an increase in systolic blood pressure, in venous capacitance in the calf and in blood flow in man.25 Whether or not these actions of lidocaine on peripheral vessels play a part in affecting reflex sinus nodal automaticity is not known.
In the present study, the effects of lidocaine on sinus node recovery time varied. In patients with normal sinoatrial function, recovery times did not change with lidocaine. This is in agreement with the observations of Roos et al.9 In contrast, lidocaine caused slight but significant shortening of sinus node recovery times in our patients with sinus node dysfunction. This could reflect increased sinus automaticity (see above) and/or increased perinodal refractoriness caused by lidocaine (see below).26 Increased perinodal refractoriness might prevent some driven atrial impulses from penetrating the sinus node, mimicking shortening of recovery time. 27 There are no previously reported data concerning the effects of lidocaine on sinoatrial conduction in man. Experimental studies in rabbit hearts by Yamaguchi et al.28 demonstrated lack of significant effects of lidocaine on conduction time from sinus node to crista terminalis.
Parameswaran and co-workers,5 utilizing simultaneous recording of transmembrane potentials from sinus node and atrium in rabbits, demonstrated the development of sinoatrial exit block with lidocaine. Sinus rhythmicity during exposure to lidocaine was unchanged, suggesting a direct inhibition of perinodal tissue. Lieberman and co-workers22 demonstrated an increase in conduction time between the sinus node and left atrial appendage following lidocaine infusion. Although they did not measure the direct sinoatrial conduction time before and after lidocaine, it is conceivable that part of the conduction delay observed occurred through perinodal fibers. In the present study, calculated sinoatrial conduction time was unchanged during lidocaine administration in patients without sinoatrial disease. In contrast, lidocaine slightly but significantly increased sinoatrial conduction time in patients with sinoatrial dysfunction. Calculated sinoatrial conduction time was normal in all patients with sinoatrial dysfunction (during control) except one in whom Zone I accounted for 100% of the scanned sinus cycle length. The incidence of prolonged calculated sinoatrial conduction time in patients with sinus node dysfunction is low, ranging from 20 to 30%.29, 20 The presence of normal sinoatrial conduction time in most of our patients with sinoatrial dysfunction reflected our criteria for patient selection (one or more abnormalities of sinus or atrial function) and our relatively higher value for normal sinoatrial conduction time (< 152 msec) compared to other studies. 14 and without sinoatrial dysfunction is in agreement with these previously reported studies.
In the present study, the dosage and mode of lidocaine administration were in accordance with the widely recommended regimen of an initial bolus injection of about 1 mg/kg of body weight, followed by a continuous infusion of 1-4 mg/min.6 Therapeutic plasma concentrations of lidocaine are considered to be between 1.2 and 5.0 gg/ml. '8 36 Although blood levels of lidocaine were not measured in our patients, the dosage schedule used in this study is expected to produce a plasma level well within this therapeutic range. Previous studies in man have shown that after a single intravenous injection of 1 mg/kg, plasma lidocaine levels are 8 ,ug/ml at 2 min, 3.5 gg/ml at 5 min, 2.5 Ag/ml at 10 min, 1.5 ug/ml at 20 min, and 1.2 ,ug/ml at 30 min.36 37 The additive effects of the bolus and continuous infusion provide a lidocaine blood level greater than 1.5 ,g/ml in approximately 20 min, rising gradually to a final level ranging from 2 to 5 ,g/iml after several hours.38 Our studies were initiated 10 min after the bolus injection and were completed within one hour, suggesting that although steady state lidocaine levels were not obtained, they were within the therapeutic range.
The present study demonstrates the following effects of lidocaine on the sinus node: 1) Lidocaine shorted sinus cycle length in patients both with and without sinus node dysfunction and did not significantly affect atrial refractoriness. 2) Lidocaine depressed perinodal tissue refractoriness only in patients with sinoatrial dysfunction. The differential actions of lidocaine in the two groups of patients may reflect increased sensitivity to lidocaine in patients with pre-existent sinoatrial disease. The previously reported occurrences of sinus arrest with lidocaine in patients with prior sinus node dysfunction add support to this hypothesis.'`8 Furthermore, lidocaine in therapeutic doses has been reported to depress intraventricular conduction only in patients with preexistent interventricular conduction disease.4' The associated perinodal tissue disease that may also be present may contribute to the alteration of electrophysiological and pharmacological properties. Atropine has been shown to produce different electrophysiological effects depending on whether or not a patient has sinus node dysfunction.39 40 
Clinical Implications
The present study implies that lidocaine has limited risk of serious sinus bradyarrhythmia in patients without sinus node disease. In contrast, lidocaine produced slight but significant lengthening of sinoatrial conduction time in patients with sinoatrial dysfunction, a finding that may account for the instances of severe sinus bradycardia and sinus arrest noted with lidocaine administration.'`8 Thus caution should be used if lidocaine is considered for patients with known or suspected sinus node disease. Similarly since elderly patients may have subclinical sinus node disease, administration of lidocaine should be undertaken only after careful consideration. ' A-V node refractory periods were shorter, and enhanced A-V conduction more frequent (7/12, 58% vs 7/28, 25%) in LGL patients compared to similar studies in 28 normal controls. During laboratory study reciprocating tachycardia (RT) due to re-entry within the A-V node occurred in 4/12 (33%) LGL patients, and exhibited a shorter cycle length (294 ± 60.4 msec) than did the same arrhythmia in 11/28 (39%) controls (372 ± 51.8 msec, P < 0.05). Similarly, RT THE FREQUENT OCCURRENCE of "rapid heart action" in patients exhibiting a short P-R interval and a normal QRS complex on surface ECG has been reported,t 2 and is commonly referred to as the Lown-Ganong-Levine (LGL) syndrome.2 Although several reports have presented results of electrophysiologic studies in patients with this syndrome,3 in few cases has the relation between the electrophysiologic observations and the arrhythmia(s) experienced by the patient been explored.14 16 Consequently, the basis for an association between a short P-R interval and paroxysmal cardiac arrhythmias remains unclear. The purpose of this investigation was to study atrioventricular (A-V) conduction and refractoriness in patients with LGL syndrome, and to evaluate the role played by these electrophysiologic utilizing a concealed accessory pathway had a shorter cycle length (228 ± 3.5 msec) in 2/12 (17%) LGL patients than in 11/28 (39%) controls (314 ± 24.3 msec, P < 0.001). In AF, the shortest R-R intervals in 4/12 (33%) LGL patients (2 group I, 2 group II) were shorter than in 15/28 (54%) control patients (254 ± 42.2 msec vs 325 ± 64.2 msec, P < 0.05). The mean R-R intervals did not differ significantly (LGL 372 ± 89 msec vs control 428 ± 82.6 msec). This study suggests that the characteristics of A-V conduction and refractoriness may permit development of more rapid heart rates during certain arrhythmias in LGL patients compared to normal controls. Furthermore, the occurrence of VT in patients with LGL syndrome indicates that symptomatic arrhythmias require specific diagnosis.
characteristics in the occurrence of symptomatic arrhythmias in this syndrome.
Methods

LGL Patients
Between January 1974 and April 1977, 12 patients (mean age 30 ± 17.0 years) with the LGL syndrome (defined below) were studied in the Clinical Electrophysiology Laboratory at Duke University Medical Center. All patients were referred for evaluation of intermittent cardiac arrhythmias. In order to be included in this analysis each of the following criteria had to be met: (1) a positive history of paroxysmal rapid heart action; (2) electrocardiographically documented tachyarrhythmias (atrial fibrillation or flutter, narrow QRS complex tachycardia, ventricular tachycardia, or ventricular fibrillation); (3) at least two electrocardiograms obtained during sinus rhythm at a time when the patient was taking no medications, demonstrating a normal P wave axis, P-R interval of 120 msec or less, and normal QRS duration (100 msec or less in patients 15 years of age or older, 90 msec or less in patients aged 5-14 years);17 (4) no electrocardiogram demonstrating a P-R interval greater than 120 msec, at a time when the patient was taking no medication.
